A Phase 3 interventional study of Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily) and Comparator: MK0431 100 mg q.d. (q.d. = once daily) in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2017-05-05.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 7th largest by enrollment of the 197 interventional ones that give a count, is one of 4 that started in 2005, is one of 74 in phase 3, and was the 7th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 78 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 4 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,208 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 10th largest by enrollment of the 170 interventional ones that give a count, is one of 7 that started in 2005, is one of 86 in phase 3, and was the 7th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety and effectiveness of an investigational drug in patients with Type 2 Diabetes Mellitus (T2DM) (a specific type of diabetes).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
54-Week Base Study:
Patients between the ages of 18 and 78 with Type 2 Diabetes Mellitus (a specific type of diabetes)
50-Week Extension Study:
Exclusion Criteria:
MK0431 100 mg q.d.
Drug: Comparator: MK0431 100 mg q.d. (q.d. = once daily)
Metformin 500 mg b.i.d.
Drug: Comparator: Metformin 500 mg b.i.d.
Metformin 1000 mg b.i.d.
Drug: Comparator: Metformin 1000 mg b.i.d.
Coadministration of MK0431 and Metformin 50/500 mg b.i.d.
Drug: Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily) · Drug: Comparator: Metformin 500 mg b.i.d.
Coadministration of MK0431 and Metformin 50/1000 mg b.i.d.
Drug: Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily) · Drug: Comparator: Metformin 1000 mg b.i.d.
Placebo/Metformin 1000 mg b.i.d.
Drug: Comparator: Placebo (Phase A)/Metformin (Phase B)
Non-Randomized, Open-Label: Coadministration MK0431 and Metformin 50/1000 mg b.i.d.
Drug: Comparator: Open-Label MK0431/Metformin 50/1000 mg b.i.d.
MK0431 oral tablets will be started on Day 1 at 50 mg q.d. (q.d. = once daily) and increased after one week to a stable dose of 50 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take MK0431 50 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
Also known as: MK0431
MK0431 oral tablets will be started on Day 1 as two 50 mg tablets (100 mg q.d.) (q.d. = once daily) and continued at this dose throughout the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
During the placebo-controlled period (Day 1 through Week 24/Phase A), metformin and MK0431 matching placebos will be dispensed as oral tablets. At the beginning of the 30-week active-controlled period (Phase B), metformin will be started as 500 mg q.d. (q.d. = once daily) and up-titrated in 500 mg weekly increments to a stable dose of 1000 mg b.i.d. Patients who complete the 54-week base study and who enter the 50-week extension study will continue to take metformin 1000 mg b.i.d. (b.i.d. = twice daily) for a total placebo/metformin treatment duration of up to 104 weeks.
Metformin oral tablets will be started on Day 1 at 500 mg q.d. (q.d. = once daily) and increased after 1 week to a stable dose of 500 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take metformin 500 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
MK0431 oral tablets will be started on Day 1 at 50 mg q.d. (q.d. = once daily) and increased after one week to a stable dose of 50 mg b.i.d. (b.i.d. = twice daily) Metformin oral tablets will be started on Day 1 at 500 mg q.d. and increased by increments of 500 mg per week to achieve a stable dose of 1000 mg b.i.d. The open-label treatment period is 24 weeks.
Metformin oral tablets will be started on Day 1 at 500 mg q.d. (q.d. = once daily) and increased by increments of 500 mg per week to achieve a stable dose of 1000 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take metformin 1000 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24
HbA1c is measured as a percent. This change from baseline reflects the Week 24 HbA1c percent minus the Week 0 HbA1c percent.
Time frame: Week 24
Change From Baseline in FPG (Fasting Plasma Glucose) at Week 24
Change from baseline at Week 24 is defined as Week 24 minus Week 0.
Time frame: Week 24
Change From Baseline in 2-Hour PMG (Post-Meal Glucose) at Week 24
Change from baseline at Week 24 is defined as Week 24 minus Week 0.
Time frame: Week 24
Change From Baseline in HbA1c (Hemoglobin A1C) at Week 54
HbA1c is measured as a percent. This change from baseline reflects the Week 54 HbA1c percent minus the Week 0 HbA1c percent.
Time frame: Week 54
Change From Baseline in FPG (Fasting Plasma Glucose) at Week 54
Change from baseline at Week 54 is defined as Week 54 minus Week 0.
Time frame: Week 54
Change From Baseline in 2-Hour PMG (Post-Meal Glucose) at Week 54
Change from baseline at Week 54 is defined as Week 54 minus Week 0.
Time frame: Week 54
Change From Baseline in HbA1c (Hemoglobin A1C) at Week 104
HbA1c is measured as a percent. This change from baseline reflects the Week 104 HbA1c percent minus the Week 0 HbA1c percent.
Time frame: Week 104
Change From Baseline in FPG (Fasting Plasma Glucose) at Week 104
Change from baseline at Week 104 is defined as Week 104 minus Week 0.
Time frame: Week 104
Change From Baseline in 2-Hour PMG (Post-Meal Glucose) at Week 104
Change from baseline at Week 104 is defined as Week 104 minus Week 0.
Time frame: Week 104
First Patient In: 01-Apr-2005 Last Patient Last Visit: 29-Feb-2008 140 study centers worldwide
| Milestone | Sitagliptin 100 mg q.d. | Metformin 500 mg b.i.d. | Metformin 1000 mg b.i.d. | Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | Placebo/Metformin 1000 mg b.i.d. | Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. OLC |
|---|---|---|---|---|---|---|---|
| Started | 179 | 182 | 182 | 190 | 182 | 176 | 117 |
| Completed | 122 | 126 | 135 | 148 | 141 | 115 | 79 |
| Not completed | 57 | 56 | 47 | 42 | 41 | 61 | 38 |
| Withdrew: Adverse event | 12 | 9 | 11 | 6 | 5 | 11 | 3 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Lack of efficacy | 11 | 14 | 8 | 4 | 3 | 14 | 19 |
| Withdrew: Lost to follow-up | 5 | 4 | 7 | 5 | 10 | 9 | 3 |
| Withdrew: Physician decision | 1 | 1 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Protocol violation | 6 | 4 | 2 | 4 | 0 | 3 | 3 |
| Withdrew: Withdrawal by subject | 17 | 16 | 16 | 15 | 10 | 15 | 4 |
| Withdrew: Protocol discontinuation criteria | 2 | 5 | 2 | 6 | 5 | 3 | 5 |
| Withdrew: Patient moved | 0 | 1 | 1 | 2 | 3 | 1 | 0 |
| Withdrew: Non-compliance with study procedures | 1 | 2 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Patient incarcerated | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Laboratory reporting error | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Site error | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Patient intolerance to rescue therapy | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sitagliptin 100 mg q.d. | Metformin 500 mg b.i.d. | Metformin 1000 mg b.i.d. | Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | Placebo/Metformin 1000 mg b.i.d. | Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. OLC |
|---|---|---|---|---|---|---|---|
| Started | 103 | 107 | 121 | 134 | 122 | 98 | 0 |
| Completed | 65 | 80 | 95 | 98 | 101 | 78 | 0 |
| Not completed | 38 | 27 | 26 | 36 | 21 | 20 | 0 |
| Withdrew: Adverse event | 2 | 3 | 2 | 0 | 1 | 1 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 26 | 15 | 13 | 16 | 8 | 8 | 0 |
| Withdrew: Lost to follow-up | 4 | 0 | 1 | 4 | 3 | 3 | 0 |
| Withdrew: Physician decision | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 1 | 1 | 2 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 5 | 2 | 8 | 3 | 3 | 0 |
| Withdrew: Protocol discontinuation criteria | 2 | 2 | 3 | 2 | 3 | 3 | 0 |
| Withdrew: Non-compliance with study procedures | 1 | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Patient moved | 0 | 0 | 1 | 2 | 0 | 0 | 0 |
| Withdrew: Patient scheduled for elective surgery | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Reason unspecified | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
HbA1c is measured as a percent. This change from baseline reflects the Week 24 HbA1c percent minus the Week 0 HbA1c percent.
| Percent | Sitagliptin 100 mg q.d. | Metformin 500 mg b.i.d. | Metformin 1000 mg b.i.d. | Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | Placebo/Metformin 1000 mg b.i.d. |
|---|---|---|---|---|---|---|
| Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 | -0.66 (-0.83 to -0.50) | -0.82 (-0.98 to -0.66) | -1.13 (-1.29 to -0.97) | -1.40 (-1.56 to -1.24) | -1.90 (-2.06 to -1.74) | 0.17 (0.00 to 0.33) |
Change from baseline at Week 24 is defined as Week 24 minus Week 0.
| mg/dL | Sitagliptin 100 mg q.d. | Metformin 500 mg b.i.d. | Metformin 1000 mg b.i.d. | Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | Placebo/Metformin 1000 mg b.i.d. |
|---|---|---|---|---|---|---|
| Change From Baseline in FPG (Fasting Plasma Glucose) at Week 24 | -17.5 (-24.1 to -10.8) | -27.3 (-34.0 to -20.7) | -29.3 (-35.9 to -22.6) | -47.1 (-53.7 to -40.6) | -63.9 (-70.5 to -57.3) | 5.8 (-1.0 to 12.7) |
Change from baseline at Week 24 is defined as Week 24 minus Week 0.
| mg/dL | Sitagliptin 100 mg q.d. | Metformin 500 mg b.i.d. | Metformin 1000 mg b.i.d. | Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | Placebo/Metformin 1000 mg b.i.d. |
|---|---|---|---|---|---|---|
| Change From Baseline in 2-Hour PMG (Post-Meal Glucose) at Week 24 | -51.9 (-62.3 to -41.5) | -53.4 (-63.6 to -43.2) | -78.0 (-88.3 to -67.6) | -92.5 (-102.6 to -82.5) | -116.6 (-126.4 to -106.7) | 0.3 (-10.4 to 11.0) |
HbA1c is measured as a percent. This change from baseline reflects the Week 54 HbA1c percent minus the Week 0 HbA1c percent.
| Percent | Sitagliptin 100 mg q.d. | Metformin 500 mg b.i.d. | Metformin 1000 mg b.i.d. | Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | Placebo/Metformin 1000 mg b.i.d. |
|---|---|---|---|---|---|---|
| Change From Baseline in HbA1c (Hemoglobin A1C) at Week 54 | -0.82 (-1.00 to -0.63) | -1.01 (-1.18 to -0.83) | -1.34 (-1.50 to -1.17) | -1.41 (-1.57 to -1.25) | -1.80 (-1.96 to -1.65) | -1.10 (-1.32 to -0.88) |
Change from baseline at Week 54 is defined as Week 54 minus Week 0.
| mg/dL | Sitagliptin 100 mg q.d. | Metformin 500 mg b.i.d. | Metformin 1000 mg b.i.d. | Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | Placebo/Metformin 1000 mg b.i.d. |
|---|---|---|---|---|---|---|
| Change From Baseline in FPG (Fasting Plasma Glucose) at Week 54 | -16.0 (-23.2 to -8.7) | -29.0 (-35.9 to -22.2) | -39.6 (-46.0 to -33.2) | -42.5 (-48.6 to -36.3) | -55.6 (-61.6 to -49.6) | -43.9 (-52.3 to -35.5) |
Change from baseline at Week 54 is defined as Week 54 minus Week 0.
| mg/dL | Sitagliptin 100 mg q.d. | Metformin 500 mg b.i.d. | Metformin 1000 mg b.i.d. | Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | Placebo/Metformin 1000 mg b.i.d. |
|---|---|---|---|---|---|---|
| Change From Baseline in 2-Hour PMG (Post-Meal Glucose) at Week 54 | -45.9 (-57.2 to -34.6) | -58.6 (-69.6 to -47.6) | -76.3 (-86.1 to -66.5) | -89.6 (-99.2 to -80.0) | -107.9 (-117.1 to -98.7) | -80.9 (-93.9 to -67.9) |
HbA1c is measured as a percent. This change from baseline reflects the Week 104 HbA1c percent minus the Week 0 HbA1c percent.
| Percent | Sitagliptin 100 mg q.d. | Metformin 500 mg b.i.d. | Metformin 1000 mg b.i.d. | Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | Placebo/Metformin 1000 mg b.i.d. |
|---|---|---|---|---|---|---|
| Change From Baseline in HbA1c (Hemoglobin A1C) at Week 104 | -1.15 (-1.37 to -0.92) | -1.06 (-1.26 to -0.87) | -1.34 (-1.51 to -1.17) | -1.39 (-1.55 to -1.22) | -1.66 (-1.81 to -1.50) | -1.39 (-1.63 to -1.15) |
Change from baseline at Week 104 is defined as Week 104 minus Week 0.
| mg/dL | Sitagliptin 100 mg q.d. | Metformin 500 mg b.i.d. | Metformin 1000 mg b.i.d. | Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | Placebo/Metformin 1000 mg b.i.d. |
|---|---|---|---|---|---|---|
| Change From Baseline in FPG (Fasting Plasma Glucose) at Week 104 | -26.8 (-36.2 to -17.4) | -41.4 (-49.8 to -33.0) | -43.2 (-50.3 to -36.2) | -47.5 (-54.3 to -40.7) | -57.3 (-63.7 to -50.8) | -45.2 (-55.7 to -34.8) |
Change from baseline at Week 104 is defined as Week 104 minus Week 0.
| mg/dL | Sitagliptin 100 mg q.d. | Metformin 500 mg b.i.d. | Metformin 1000 mg b.i.d. | Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | Placebo/Metformin 1000 mg b.i.d. |
|---|---|---|---|---|---|---|
| Change From Baseline in 2-Hour PMG (Post-Meal Glucose) at Week 104 | -74.1 (-90.3 to -57.9) | -72.7 (-87.4 to -58.1) | -86.7 (-99.0 to -74.5) | -96.2 (-107.8 to -84.6) | -110.0 (-120.9 to -99.1) | -93.3 (-111.8 to -74.9) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin 100 mg q.d. | — | — | — |
| Metformin 500 mg b.i.d. | — | — | — |
| Metformin 1000 mg b.i.d. | — | — | — |
| Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | — | — | — |
| Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | — | — | — |
| Placebo/Metformin 1000 mg b.i.d. | — | — | — |
| Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. OLC | — | — | — |
| Event | Sitagliptin 100 mg q.d. | Metformin 500 mg b.i.d. | Metformin 1000 mg b.i.d. | Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | Placebo/Metformin 1000 mg b.i.d. | Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. OLC |
|---|---|---|---|---|---|---|---|
| Any Cardiac DisordersCardiac disorders | 2/179 | 1/182 | 3/182 | 3/190 | 3/182 | 4/176 | 0/117 |
| Any Infections And InfestationsInfections and infestations | 3/179 | 2/182 | 1/182 | 1/190 | 3/182 | 4/176 | 1/117 |
| Any Neoplasms Benign, Malignant And UnspecifiedNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 4/179 | 3/182 | 2/182 | 2/190 | 1/182 | 4/176 | 1/117 |
| Any Nervous System DisordersNervous system disorders | 2/179 | 0/182 | 0/182 | 2/190 | 0/182 | 4/176 | 0/117 |
| Any Injury, Poisoning And Procedural ComplicationsInjury, poisoning and procedural complications | 1/179 | 1/182 | 4/182 | 1/190 | 2/182 | 1/176 | 0/117 |
| Coronary Artery DiseaseCardiac disorders | 0/179 | 0/182 | 0/182 | 1/190 | 0/182 | 3/176 | 0/117 |
| Any General Disorders And Administration Site ConditionsGeneral disorders | 0/179 | 1/182 | 0/182 | 3/190 | 0/182 | 3/176 | 0/117 |
| Any Hepatobiliary DisordersHepatobiliary disorders | 0/179 | 1/182 | 1/182 | 0/190 | 0/182 | 3/176 | 0/117 |
| Any Gastrointestinal DisordersGastrointestinal disorders | 1/179 | 0/182 | 1/182 | 1/190 | 2/182 | 2/176 | 0/117 |
| CholelithiasisHepatobiliary disorders | 0/179 | 0/182 | 1/182 | 0/190 | 0/182 | 2/176 | 0/117 |
| Event | Sitagliptin 100 mg q.d. | Metformin 500 mg b.i.d. | Metformin 1000 mg b.i.d. | Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | Placebo/Metformin 1000 mg b.i.d. | Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. OLC |
|---|---|---|---|---|---|---|---|
| Any Infections And InfestationsInfections and infestations | 40/179 | 44/182 | 53/182 | 54/190 | 60/182 | 37/176 | 19/117 |
| Any Gastrointestinal DisordersGastrointestinal disorders | 19/179 | 23/182 | 42/182 | 31/190 | 35/182 | 17/176 | 18/117 |
| DiarrhoeaGastrointestinal disorders | 8/179 | 14/182 | 23/182 | 19/190 | 25/182 | 12/176 | 10/117 |
| Any Musculoskeletal And Connective Tissue DisordersMusculoskeletal and connective tissue disorders | 16/179 | 20/182 | 21/182 | 19/190 | 25/182 | 13/176 | 6/117 |
| Upper Respiratory Tract InfectionInfections and infestations | 12/179 | 17/182 | 20/182 | 21/190 | 24/182 | 13/176 | 4/117 |
| BronchitisInfections and infestations | 3/179 | 3/182 | 10/182 | 7/190 | 20/182 | 8/176 | 3/117 |
| Any Nervous System DisordersNervous system disorders | 9/179 | 13/182 | 20/182 | 17/190 | 19/182 | 10/176 | 4/117 |
| NauseaGastrointestinal disorders | 2/179 | 6/182 | 19/182 | 10/190 | 12/182 | 4/176 | 7/117 |
| HeadacheNervous system disorders | 6/179 | 9/182 | 12/182 | 15/190 | 12/182 | 7/176 | 3/117 |
| InfluenzaInfections and infestations | 8/179 | 11/182 | 14/182 | 11/190 | 9/182 | 5/176 | 3/117 |
| Age, Continuous(years) | Sitagliptin 100 mg q.d. | Metformin 500 mg b.i.d. | Metformin 1000 mg b.i.d. | Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | Placebo/Metformin 1000 mg b.i.d. | Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. OLC | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 53.3 ± 10.2 | 53.4 ± 10.2 | 53.2 ± 9.6 | 54.1 ± 10.0 | 53.3 ± 9.6 | 53.6 ± 10.0 | 52.6 ± 10.0 | 53.4 ± 9.9 |
| Sex: Female, Male(Participants) | Sitagliptin 100 mg q.d. | Metformin 500 mg b.i.d. | Metformin 1000 mg b.i.d. | Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | Placebo/Metformin 1000 mg b.i.d. | Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. OLC | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 86 | 93 | 100 | 85 | 105 | 83 | 50 | 602 |
| Male | 93 | 89 | 82 | 105 | 77 | 93 | 67 | 606 |
| Race/Ethnicity, Customized(participants) | Sitagliptin 100 mg q.d. | Metformin 500 mg b.i.d. | Metformin 1000 mg b.i.d. | Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | Placebo/Metformin 1000 mg b.i.d. | Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. OLC | Total |
|---|---|---|---|---|---|---|---|---|
| White | 93 | 87 | 106 | 102 | 95 | 81 | 44 | 608 |
| Black | 11 | 12 | 9 | 13 | 14 | 17 | 9 | 85 |
| Hispanic | 52 | 55 | 39 | 55 | 49 | 47 | 54 | 351 |
| Asian | 6 | 14 | 10 | 9 | 11 | 12 | 1 | 63 |
| Other | 17 | 14 | 18 | 11 | 13 | 19 | 9 | 101 |
| HbA1c (Hemoglobin A1c)(Percent) | Sitagliptin 100 mg q.d. | Metformin 500 mg b.i.d. | Metformin 1000 mg b.i.d. | Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d. | Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. | Placebo/Metformin 1000 mg b.i.d. | Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. OLC | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 8.9 ± 1.0 | 8.9 ± 1.0 | 8.7 ± 0.9 | 8.8 ± 1.0 | 8.7 ± 0.9 | 8.7 ± 1.0 | 11.2 ± 1.2 | 9.0 ± 1.2 |
No study locations are listed for this record.
Ran from Mar 2005 to primary completion in Jul 2006, 16 months.
Results were first posted in May 2009, 2 years 9 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 16 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sitagliptin · Metformin